埃斯瓦蒂尼HIV感染者2剂与3剂HPV疫苗免疫原性比较
在埃斯瓦蒂尼开展多中心开放标签非劣效研究,HIV感染者(PWH)三个队列接种2剂9vHPV,无HIV的青春期女孩和年轻女性(AGYW)接种3剂作为对照。7个月时检测抗体,PWH中男童和女童2剂免疫原性对所有HPV亚型均非劣于无HIV的AGYW 3剂,但HIV AGYW对HPV-45非劣效未达标,且病毒载量>50 copies/mL者滴度较低。
要点
- HIV感染男童和女童2剂9vHPV免疫原性非劣于无HIV AGYW的3剂方案。
- HIV感染AGYW 2剂对HPV-45非劣效未达标,其余亚型非劣。
- 病毒载量>50 copies/mL的PWH抗体滴度较低,非劣效未确立。
核心结论
- PWH接种2剂9vHPV总体非劣于无HIV AGYW的3剂方案,但病毒血症者2剂免疫原性可能受损。
- 在维持病毒载量抑制的前提下,资源节约型2剂接种是PWH的合适选择。
研究设计与样本
- 多中心、开放标签、非劣效研究,在埃斯瓦蒂尼开展。
- PWH三队列接种2剂9vHPV(0、6月):男童9-14岁n=349;女童9-14岁n=352;AGYW 15-26岁n=350。
- 对照队列为无HIV的AGYW,接种3剂(0、2、6月)。
- 7个月时用竞争性Luminex免疫分析法检测HPV-6/11/16/18/31/33/45/52/58抗体。
主要发现
- PWH 2剂完成率高:男童95%、女童97%、AGYW 93%。
- 无HIV AGYW中95%接种第二剂、84%完成3剂。
- HIV男童GMTR范围:HPV-45为0.74(0.60, 0.90)至HPV-58为1.30(1.08, 1.56)。
- HIV女童GMTR范围:HPV-45为0.70(0.58, 0.86)至HPV-58为1.32(1.10, 1.58)。
- HIV AGYW除HPV-45外非劣效,GMTR范围:HPV-18为0.66(0.54, 0.81)至HPV-11为0.95(0.78, 1.14),HPV-45为(0.40, 0.60)。
关键数值与推荐
- 非劣效判定标准:抗HPV几何平均滴度比(GMTR)95%CI下限>0.5。
- 病毒载量>50 copies/mL的PWH所有HPV亚型滴度较低,GMTR非劣效未成立。
临床怎么用
- 对病毒载量抑制的PWH,可考虑2剂9vHPV接种以节约资源。
- 对病毒载量>50 copies/mL者,2剂免疫原性可能不足,需关注接种策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited immunogenicity data among people with HIV (PWH) following human papilloma virus (HPV) vaccination, particularly with fewer dose schedules. We compared immunogenicity of 9-valent HPV vaccine (9vHPV) by HIV infection status in Eswatini. METHODS: In this multi-site, open-label, non-inferiority study, three PWH cohorts received 2-doses of 9vHPV at 0 and 6 months: 1) boys 9-14 years (n = 349); 2) girls 9-14 years (n = 352); 3) adolescent girls and young women (AGYW) 15-26 years (n = 350). A comparison cohort of AGYW without HIV received the reference standard 3-dose regimen at 0, 2 and 6 months. At 7 months, we measured HPV-6/11/16/18/31/33/45/52/58 antibodies by competitive Luminex Immunoassay. We assessed non-inferiority of anti-HPV geometric mean titer ratios (GMTR), lower-bound 95% confidence interval > 0.5, among PWH versus AGYW without HIV; and secondarily explored GMTRs by HIV viral load (VL) at baseline or 7 months. RESULTS: PWH 2-dose completion was high: 95% boys, 97% girls and 93% AGYW. Among AGYW without HIV, 95% received the second dose and 84% completed the 3-doses. GMTR of boys and girls with HIV were non-inferior to AGYW without HIV for all HPV subtypes: boys ranged from 0.74 (0.60, 0.90) for HPV-45 to 1.30 (1.08, 1.56) for HPV-58; girls ranged from 0.70 (0.58, 0.86) for HPV-45 to 1.32 (1.10, 1.58) for HPV-58. GMTR of AGYW with HIV were non-inferior to AGYW without HIV for all subtypes except HPV-45; ranging from 0.66 (0.54, 0.81) for HPV-18 to 0.95 (0.78, 1.14) for HPV-11, and (0.40, 0.60) for HPV-45. Among PWH with VL > 50 copies/mL, titers for all HPV sub-types were lower, and GMTRs were not non-inferior. CONCLUSION: We found overall non-inferior immunogenicity of 2-dose 9vHPV among PWH versus 3-doses in AGYW without HIV, but 2-dose immunogenicity among viremic PWH may be compromised. Resource-saving 2-dose vaccination is an appropriate option for PWH while sustaining their VL suppression. TRIAL REGISTRATION NUMBER: clinicaltrials.govNCT04982614.
引用
- Nuwagaba-Biribonwoha H, Lamb MR, Dlamini X, et al. Immunogenicity of 2 versus 3 dose HPV vaccination by HIV infection status in Eswatini. Vaccine. 2026. PMID: 42142523. doi:10.1016/j.vaccine.2026.128692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。